Canopy Biosciences has acquired Zellkraftwerk GmbH, a leader in multiplex cytometry. Leveraging its innovative ChipCytometry platform, Zellkraftwerk offers complete workflow solutions—including both products and research services—for high-content cytometry on cells and tissues. The combination of Canopy and Zelkraftwerk creates a unique "multi-omics" company that boasts a powerful union of genomics expertise with cutting-edge cell and tissue analysis solutions to best support customers in drug development research and biomarker discovery. Concurrent with the acquisition, Canopy closed a strategic growth investment from Ampersand Capital Partners.
"I am excited to complete the transformational acquisition of Zellkraftwerk and begin our partnership with Ampersand,” Edward Weinstein, Ph.D., co-founder and CEO of Canopy Biosciences, said. “Ampersand's expertise and resources will benefit Canopy as we build a broader product and service offering for our customers, and the Zellkraftwerk acquisition provides a meaningful contribution to this strategy." Weinstein continued, "Zellkraftwerk founders Jan Detmers and Christian Hennig have built a truly differentiated offering within the cell and tissue analysis market, and we're excited to add their unique expertise and technology platform to Canopy Biosciences."
"As the scientific community continues to appreciate the roles and relationships between genotypes, phenotypes, and the environment, the need for "multi-omic" approaches to biomarker discovery and functional biology research has never been clearer,” Cofounder of Zellkraftwerk, Jan Detmers said. “We are excited to partner with Canopy Biosciences and Ampersand to enhance our capabilities, scale, and geographic reach in the US, Europe, and Asia as we strive to best serve the evolving needs of our customers."